At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Mesenchymal Stem Cells +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Trial of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease
The University of Texas Health Science Center, Houston·interventional·Posted Aug 10, 2020·Updated Jul 26, 2024
In Brief
A Phase 2 clinical trial evaluating Mesenchymal Stem Cells and Placebo for Parkinson's Disease. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (MSC) infusions to slow the progression of Parkinson's disease (PD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
CollaboratorsMichael J. Fox Foundation for Parkinson's Research
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartNov 2020
Primary CompletionJul 2023
TodayJul 2026
First PostedAug 10, 2020
Enrollment StartNov 9, 2020
Primary CompletionJul 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.9 years ago
Interventions
Mesenchymal Stem Cellsdrug
1 dose is 10 X 10\^6 MSC/kg
Placebodrug
Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).